Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Gotistobart · ONC-392, BNT316

Monoclonal antibody · Antagonist of cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) · developed by OncoC4

Phase 3 Most advanced trial
1 Registered trials

What is Gotistobart?

Gotistobart is a humanized, pH-sensitive IgG1 monoclonal antibody that binds CTLA-4 on T cells, blocking CTLA-4-mediated suppression of T-cell activation. It dissociates from CTLA-4 at low pH, which is studied for selective regulatory T-cell depletion within tumors. It is being studied in non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ONC-392, BNT316
Drug type
Monoclonal antibody
Targets
cytotoxic T-lymphocyte-associated antigen 4 (CTLA4)
Mechanism
Antagonist of cytotoxic T-lymphocyte-associated antigen 4 (CTLA4)
Pathways
T-cell activation, regulatory T-cell depletion in the tumor microenvironment
Therapy area
Oncology
Developer
OncoC4, Inc.
In trials of
BNTX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
4R46M31XXP

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05671510 Phase 3 Non Small Cell Lung Cancer Active not recruiting BNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non Small Cell Lung Cancer

Other drugs acting on CTLA4

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.